Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1184 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Enzalutamide in addition to androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer	Enzalutamide (Xtandi; MDV3100)	Prostate cancer	Male Reproductive Cancer	2019	View \| Download
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy and/or radiotherapy	Enzalutamide (Xtandi; MDV3100)	Non-metastatic prostate cancer	Male Reproductive Cancer	2022	View \| Download
Enzalutamide (Xtandi) for non-metastatic prostate cancer	Enzalutamide (Xtandi; MDV3100)	Prostate cancer	Male Reproductive Cancer	2017	View \| Download
Entresto for chronic heart failure with preserved ejection fraction	Entresto; LCZ 696 (fixed dose combination: Sacubitril; Valsartan)	Heart failure (HF)	Cardiovascular System	2019	View \| Download
Entrectinib for the Treatment of NTRK-fusion Positive Solid Tumours in Adult and Paediatric Patients	Entrectinib (RXDX-101)	Solid tumours	Haematological Cancer and Lymphomas , Oncology	2018	View \| Download
Entrectinib for ROS1 fusion positive, locally advanced or metastatic non-small cell lung cancer	Entrectinib (RXDX-101)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2018	View \| Download
Entinostat for Hormone Refractory, HR+ Breast Cancer in Men and Postmenopausal Women	Entinostat (SNDX-275; RG7746)	Breast cancer	Breast Cancer	2017	View \| Download
Enfortumab vedotin with pembrolizumab for treating bladder cancer	Enfortumab vedotin (ASG-22ME; Padcev) , Pembrolizumab (Keytruda; MK-3475)	Bladder cancer	Urological Cancer	2023	View \| Download
Enfortumab vedotin with pembrolizumab for previously untreated locally advanced or metastatic urothelial cancer	Enfortumab vedotin (ASG-22ME; Padcev) , Pembrolizumab (Keytruda; MK-3475)	Urothelial cancer	Urological Cancer	2022	View \| Download
Enfortumab vedotin for locally advanced or metastatic urothelial cancer	Enfortumab vedotin (ASG-22ME; Padcev)	Urothelial cancer	Urological Cancer	2020	View \| Download